ArticleTranslational oncology2026
Entosis remodels the immune microenvironment of osteosarcoma by regulating macrophage polarization: An integrated study based on multi-omics data and in vitro experiments.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEntosis is a non-apoptotic form of programmed cell death. Its clinical significance and mechanism of immune microenvironment remodeling in osteosarcoma remain poorly understood.
methodsMulti-omics data from TARGET-OS and GEO were integrated with in vitro experiments. ssGSEA, WGCNA, scRNA-seq, pseudotime analysis, and cell-cell communication were used to assess Entosis activity and immune association. A prognostic risk model was constructed and validated. In vitro experiments (qPCR, flow cytometry, Western blot, ELISA) validated Entosis regulation of macrophage polarization.
resultsHigh Entosis activity was significantly correlated with favorable prognosis and a highly activated immune microenvironment in osteosarcoma patients. scRNA-seq identified macrophages as the core target cells of Entosis regulation, and the Macro_CXCL2 subset was characterized as the functional subpopulation with the highest Entosis score at the terminal differentiation stage. Cell communication analysis revealed that, under high Entosis conditions, macrophages enhanced crosstalk with other immune cells via the SPP1-CD44 and TNF signaling axes. A six-gene prognostic model (CD163, FCGR2A, NPC2, CD209, SAMHD1, IKZF1) demonstrated robust performance across multiple datasets. In vitro experiments further confirmed that high-Entosis tumor cells upregulated CXCL12 secretion in a paracrine manner, driving macrophages toward a specific functional phenotype. Mechanistically, Entosis activation was dependent on the ROCK signaling pathway and synergized with the hypoxia, TNFα-NFκB, and MAPK pathways to coordinately regulate malignant cell stemness and immune microenvironment remodeling.
conclusionEntosis exerts tumor-suppressive and immune-activating effects in osteosarcoma by remodeling macrophage function, offering new targets for precision prognosis and Entosis-directed immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.